Document:

Exhibit
10.30

 

EXHIBIT
B: THE NOTE

 

THIS
NOTE HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE, IN RELIANCE
UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY,
MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE
EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH
APPLICABLE STATE SECURITIES LAWS, AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF
WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY

 

SECURED
CONVERTIBLE PROMISSORY NOTE

DUE
NOVEMBER 6, 2020

 

FOR
VALUE RECEIVED, NutraLife BioSciences, Inc., a Florida corporation (“NutraLife”) and PhytoChem Technologies, Inc.
(“PhytoChem”), a Florida corporation (NutraLife and PhytoChem are collectively referred to herein as the “Company”),
promise to pay to and Kahn Family Limited PT II (the “Purchaser”), the principal sum of $1,000,000 on or before November
6, 2020 as set forth below (the “Maturity Date”) pursuant to the terms of this Secured Convertible Promissory Note
(the “Note”). The Company and the Purchaser are referred to herein collectively as the “Parties”, or individually
as a “Party”.

 

WHEREAS,
the Company obtained certain rights to commercialize and monetize certain technology and phytoextractor equipment known as
the Ennea Processor (“Ennea” or “Ennea Processor”) pursuant to an agreement by and between Owen J. Morgan
(“Morgan”) and the Company dated February 4, 2019 (the “Morgan Agreement”);

 

WHEREAS,
the Company requires capital to manufacture, purchase, monetize and commercialize the Ennea Processors;

 

WHEREAS,
the Company desires to issue and sell, and the Purchaser desires to purchase this Note which shall bear interest (the “Interest”)
at the rate of eight and one half percent (8.5%) per annuum (the “Interest”) in the principal amount of $1,000,000
(“Principal” or the “Principal Amount”);

 

WHEREAS,
the first four Ennea Processors (the “Collateral Processors”) that the Company commercializes pursuant to the
Morgan Agreement shall serve as collateral for the Principal Amount pursuant to the terms of the Security Agreement (the “Security
Agreement”) attached to the Investment Agreement as Exhibit C;

 

WHEREAS,
at any time while the Note is outstanding, the Purchaser shall have the right to convert the Note into shares of the Company’s
Common Stock at the price of $1.00 per share (the “Conversion Shares”);

 

WHEREAS,
as consideration for the purchase of the Note, the Company shall (i) pay to the Purchaser the Interest as set forth in this
Note, (ii) issue 500,000 shares of its Common Stock, $.0001 par value per share (the “Common Shares”) to the Purchaser,
and (iii) grant the Purchaser eight and one half percent (8.5%) of the revenue generated from the Collateral Processors (the “Royalty”)
while the Principal Amount is outstanding and five percent (5%) thereafter as set forth in the Royalty Agreement (the “Purchaser
Royalty Agreement”) attached to the Investment Agreement as Exhibit D.

 

    	 	 	 

    	 

    

 

WHEREAS,
the Principal Amount shall be secured by a mortgage (the “Mortgage”) on certain real property (the “Real
Property”) attached hereto as Exhibit E provided by a pledgor (the “Pledgor”) who will provide the Mortgage
and receive consideration for the pledge of the Real Property pursuant to the terms of the Pledge Agreement attached to the Investment
Agreement Exhibit F (the “Pledge Agreement”).

 

WHEREAS,
the Principal Amount secured by the Mortgage will be reduced by any and all consideration of any nature that is paid to the
Purchaser by the Company under the Transaction Documents (as defined in the Investment Agreement).

 

NOW
THEREFORE, in consideration of the mutual promises contained herein and other good and valuable consideration, receipt of
which is hereby acknowledged, the undersigned agrees as follows:

 

ARTICLE
1. RECITALS

 

The
Recitals below are incorporated herein and made a part hereof constituting binding terms of this Note.

 

ARTICLE
2. MATURITY.

 

ARTICLE
2.1 MATURITY DATE. On December 7, 2020 (the “Maturity Date”), the entire outstanding principal balance of this
Note shall mature.

 

ARTICLE
3. PAYMENT.

 

ARTICLE
3.1 AMORTIZATION. From the date of this Note (the “Effective Date”) until such time as the Principal Amount has
been paid in full, Interest will accrue at the fixed rate of eight- and one-half percent (8.5%) per annum. Beginning July 7, 2019
through December 7, 2019, the Company will make interest only payments on the Principal Amount. Beginning on January 7, 2020 and
continuing until the Maturity Date, the Company will make equal monthly installment payments of principal and interest in an amount
sufficient to fully amortize the Principal Amount and all accrued Interest over an amortization period of twelve (12) months.

 

ARTICLE
3.2 PAYMENT SCHEDULE. From July 7, 2019 through December 7, 2019, the Company will make interest only payments at the fixed
rate of eight- and one-half percent (8.5%) per annum. Beginning on January 7, 2020 and continuing until the Maturity Date, the
Company will make equal monthly installment payments of principal and interest at the fixed rate of eight- and one-half percent
(8.5%) per annum until the amounts due under the Note are paid in full.

 

ARTICLE
3.3 INTEREST. Interest will accrue at the rate of eight- and one-half percent (8.5%) per annum beginning on the Effective
Date. Interest shall be calculated based upon a 365-day year and the actual number of days elapsed. All amounts payable under
this Note are payable in lawful money of the United States during normal business hours on a Business Day. For purposes of this
Note, “Business Day” means any day except Saturday, Sunday, and any day which shall be a federal legal holiday in
the United States or a day on which banking institutions in the State of Florida are authorized or required by law or other government
action to close.

 

    	 	 	 

    	 

    

 

ARTICLE
3.4 PREPAYMENT. The Company may prepay this Note in whole or in part at any time without interest or penalty.

 

ARTICLE
3.5 APPLICATION OF PAYMENTS. All payments made by the Company to the Purchaser under the Transaction Documents including but
not limited to this Note shall be first applied, to the Principal Amount then to accrued interest outstanding. Any and all consideration
paid by the Company to the Purchaser under the Transaction Documents (as defined in the Investment Agreement) shall reduce the
amounts secured by the Mortgage without affecting the amounts owed by the Company to the Purchaser under the Transaction Documents.
For example, for the avoidance of doubt, should the Purchaser receive consideration from Purchaser in Interest, Royalty and/or
Securities having a value of $500,000 then the Mortgage would be reduced to $500,000 ($1,000,000-$500,000) without affecting the
amounts owed by the Company to the Purchaser.

 

ARTICLE
4. COLLATERAL.

 

ARTICLE
4.1 ENNEA PROCESSOR AS COLLATERAL. This Note is secured by the Collateral Processors
pursuant to the terms as set forth in the Investment Agreement and Security Agreement.
The “Collateral Processors” as used in this Note shall mean the first four (4) Ennea Processors manufactured and/or
commercialized by the Company directly or indirectly as a result of or pursuant to the Morgan Agreement.

 

ARTICLE
4.2 REAL PROPERTY AS COLLATERAL. The Company shall deliver a pledge of the Real Property to
secure the Principal Amount pursuant to the terms of the Pledge Agreement and Mortgage
attached as Exhibits E and F of the Investment Agreement and such Mortgage shall be reduced from time to time by the consideration
paid by the Company to the Purchaser. Simultaneously with the payment of consideration equal to the Principal Amount, the Purchaser
will record with the Palm Beach County Property Appraiser’s Officer, a Satisfaction of the Mortgage releasing the Purchaser’s
Mortgage on the Real Property.

 

ARTICLE
4.3 FULL RECOURSE NOTE. This is a Full Recourse Promissory Note. Accordingly, in the event of a default of this Note, Purchaser
shall have full recourse to all the assets of the Company (including the assets of both NutraLife and PhytoChem) and the Purchaser
shall be required to proceed against or exhaust all remedies against both NutraLife and PhytoChem’s assets prior to proceeding
against the Mortgage and/or commencing an action to foreclose the Mortgage on the Real Property.

 

ARTICLE
4.4 RECORDS. The Company and Purchaser shall provide Pledgor with copies of all consideration paid by the Company to Purchaser
under the Transaction Documents.

 

ARTICLE
5. CONVERSION.

 

ARTICLE
5.1 CONVERSION BY THE PURCHASER. At any time while this Note is outstanding, the Purchaser shall have the option of converting
the Principal Amount and accrued Interest due on this Note into the Company’s Common Stock at the price of $1.00 per share.
The Common Stock issued upon conversion of this Note are referred to herein as the “Conversion Shares”.

 

    	 	 	 

    	 

    

 

ARTICLE
5.2 MECHANICS AND EFFECT OF CONVERSION. Upon conversion of this Note pursuant to this Article 5, the Purchaser shall surrender
this Note, duly endorsed, at the principal offices of the Company. At its expense, the Company will, as soon as practicable thereafter,
issue and deliver to such Purchaser, at such principal office, a certificate or certificates for the Conversion Shares. Upon conversion
of the Principal Amount and/or Interest into Conversion Shares, the Company will be forever released from all of its obligations
and liabilities under this Note. In the event Purchaser converts less than all Principal and Interest outstanding, the amount
converted under the Note shall be first applied to reduce the Principal until it is paid in full. Additionally, upon conversion
of all outstanding Principal at the time of conversion, the Mortgage shall be released as security for the obligations and liabilities
under this Note.

 

ARTICLE
6. EVENTS OF DEFAULT.

 

ARTICLE
6.1. DEFAULT. An “Event of Default” shall mean that the Company has failed to make any payment required
under this Note, within fifteen (15) days after the date the payment is due. If the Company is in default under this Note, the
unpaid principal and accrued and unpaid interest and any other unpaid amounts and costs due will bear interest at the rate of
ten percent (10%) (the “Default Rate”) until the Event of Default is cured. From and after the Maturity Date
any unpaid principal and interest and any other unpaid amounts and costs under this Note will bear interest at the Default Rate.
Additionally, and without limitation, all amounts owed under any judgment obtained by Purchaser against the Company with respect
to this Note will bear interest at the Default Rate.

 

ARTICLE
6.2 COLLECTION COSTS. If an Event of Default occurs under this Note, the Company shall pay all reasonable costs of collection
including, without limitation, attorney fees in a reasonable amount without limiting the foregoing.

 

ARTICLE
7. MISCELLANEOUS.

 

ARTICLE
7.1 NOTICES. Any and all notices or other communications or deliveries to be provided by the parties shall be delivered by
facsimile, sent by a nationally recognized overnight courier service, addressed to the Company, at the addresses set forth on
the signature page hereto or such other address or facsimile number as the Company may specify for such purposes by notice to
the Purchaser delivered in accordance with this Article.

 

ARTICLE
7.2 ABSOLUTE OBLIGATION. Except as expressly provided herein, no provision of this Note shall alter or impair the obligation
of the Company, which is absolute and unconditional, to pay the principal of and any accrued interest on this Note at the time,
place, and rate, and in the coin or currency, herein prescribed.

 

ARTICLE
7.3 LOST OR MUTILATED NOTE. If this Note shall be mutilated, lost, stolen or destroyed, the Company shall execute and deliver,
in exchange and substitution for and upon cancellation of a mutilated Note, or in lieu of or in substitution for a lost, stolen
or destroyed Note, a new Note for the principal amount of this Note so mutilated, lost, stolen or destroyed but only upon receipt
of evidence of such loss, theft or destruction of such Note, and of the ownership hereof, and indemnity, if requested, all reasonably
satisfactory to the Company.

 

ARTICLE
7.4 SECURITY INTEREST. This Note is a direct debt obligation of the Company and is secured by a security interest in the Collateral
Processors. The Purchaser and the Company have entered into the Security Agreement dated as of the date hereof and attached hereto
as Exhibit C to the Investment Agreement in connection with the Purchaser’s security interest in the Collateral Processors.

 

    	 	 	 

    	 

    

 

ARTICLE
7.5 SENIORITY. The Company shall not incur any indebtedness senior to this Note while it remains outstanding and shall not
encumber the Collateral Processors or the Company’s assets with any interest senior to this Note.

 

ARTICLE
7.6 ACTION TO COLLECT ON NOTE. If action is instituted to collect on this Note, the Company shall all pay all costs and expenses,
including reasonable attorney’s fees, incurred in connection with such action.

 

ARTICLE
7.7 EXTENSION AND TERMINATION. The payments due under this Note may not be extended by the Purchaser and the Company without
the express written consent of the Pledgor identified in the Pledge Agreement. In the event that an extension of this Note is
granted without Pledgor’s written consent then the Mortgage shall be deemed satisfied and released in full as collateral
for the Principal Amount and Purchaser shall be obligated to record a release of the Mortgage in the Palm Beach County Florida
property records.

 

ARTICLE
7.8 GOVERNING LAW AND JURISDICTION. This Note shall be governed by and construed in accordance with the laws of the State
of Florida without regard to principles of conflict law applicable to contracts made and to be performed with such state. Each
of the parties hereto accepts for itself to the jurisdiction of Palm Beach County Florida and irrevocably consents to such jurisdiction
in any proceedings and waives any objection to venue laid therein. Any controversy or claim arising out of or relating of this
Note shall be settled by binding arbitration administered by the American Arbitration Association and judgment on the award entered
in any court having jurisdiction. The arbitration proceedings shall be conducted before a panel of three neutral arbitrators in
Palm Beach County, Florida all of whom shall be members of the bar of the state of Florida, actively engaged in the practice of
law for at least ten (10) years. Either Party hereto may apply to the arbitrator seeking injunctive relief until the arbitration
award is rendered or the controversy otherwise resolved. Either Party may, without waiving any remedy under this Note, seek from
any court having jurisdiction any interim or provisional relief that is necessary to protect the rights or property of that party,
pending the arbitral tribunal’s determination of the merits of the controversy. Each party shall bear its own costs, expenses
and attorney fees and an equal share of the arbitrators’ and administrative fees of arbitration. Except as may be required
by law, neither a party nor an arbitrator may disclose the existence content or results of any arbitration hereunder without the
prior written consent of the Parties. All documents, testimony and records shall be received, heard and maintained by the arbitrators
in secrecy, available for the inspection only of the Parties to this Note and their respective attorneys and their respective
experts who shall agree in advance and in writing to receive all such information confidentially and to maintain such information
in secrecy until such information shall become generally known. In consideration for and as a material condition of this Note,
each Party agrees that final and binding arbitration is the exclusive means for resolving any claim or controversy arising out
of or related to this Note. This Agreement is a waiver of all rights the Parties may have to a civil court action. Accordingly,
only an arbitrator, not a judge or jury, will decide the dispute, although the arbitrator has the authority to award any type
of relief that could otherwise be awarded by a judge or jury.

 

    	 	 	 

    	 

    

 

ARTICLE
7.9 SEVERABILITY. If any provision of this Note is invalid, illegal or unenforceable, the balance of this Note shall remain
in effect, and if any provision is inapplicable to any Person or circumstance, it shall nevertheless remain applicable to all
other Persons and circumstances. If it shall be found that any interest or other amount deemed interest due hereunder violates
applicable laws governing usury, the applicable rate of interest due hereunder shall automatically be lowered to equal the maximum
permitted rate of interest. The Company covenants (to the extent that it may lawfully do so) that it shall not at any time insist
upon, plead, or in any manner whatsoever claim or take the benefit or advantage of, any stay, extension or usury law or other
law which would prohibit or forgive the Company from paying all or any portion of the principal of or interest on this Note as
contemplated herein, wherever enacted, now or at any time hereafter in force, or which may affect the covenants or the performance
of this Note, and the Company (to the extent it may lawfully do so) hereby expressly waives all benefits or advantage of any such
law, and covenants that it will not, by resort to any such law, hinder, delay or impede the execution of any power herein granted
to the Purchaser.

 

ARTCLE
7.10 HEADINGS. The headings contained herein are for convenience only, do not constitute a part of this Note and shall not
be deemed to limit or affect any of the provisions hereof.

 

ARTICLE
7.11 PAYMENT. All payments shall be made in lawful money of the United States of America at such place as the Purchaser hereof
may from time to time designate in writing to the Company. Payments made by the Company under the Transaction Documents including
this Note shall be credited first to the Principal Amount then outstanding until paid in full then to accrued interest. Whenever
any payment or other obligation hereunder shall be due on a day other than a Business Day, such payment shall be made on the next
succeeding Business Day.

 

ARTICLE
7.12 WAIVER OF CONFLICTS. The Company and the Purchaser each acknowledge that the Pledgor, Brenda Hamilton and her law firm,
Hamilton & Associates Law Group, P.A has in the past performed, and may continue to perform, legal and/or consulting services
for the Company in connection with the Transaction Documents and the matters and transactions described in this Note as well as
in matters unrelated to the Transaction Documents. Accordingly, the Company and Purchaser each hereby acknowledges that they have
been advised by Brenda Hamilton & Hamilton & Associates Law Group, P.A. to seek the advice of independent legal counsel
in connection with the Transaction Documents including with respect to the Pledge Agreement, Mortgage and Pledgor Royal Agreement
in which Brenda Hamilton is a Party and the transactions contemplated thereby. Additionally, the Company and Purchaser each acknowledge
that they have had an opportunity to ask for information relevant to this disclosure and has consulted with independent legal
counsel or has had the opportunity to do so and gives its informed consent to Brenda Hamilton & Hamilton & Associates
Law Group, P.A. representation of and/or performance of services for the Company in the connection with the Transaction Documents
and transactions contemplated thereby.

 

ARTICLE
7.13 FORCE MAJEURE. The Company shall not be liable or responsible to Purchaser, nor be deemed to have defaulted under or
breached this Note, for any failure or delay in fulfilling or performing any term of this Note, if such failure or delay is caused
by or results from acts beyond the Company’s control, including: (i) acts of nature; (ii) flood, fire, hurricane, earthquake
or explosion; (iii) war, invasion, hostilities (whether war is declared or not), terrorist threats or acts, riot or other civil
unrest; (iv) actions, embargos or blockades in effect on or after the date of this Note; (v) national or regional emergency; (vi)
strikes, labor stoppages or slowdowns or other industrial disturbances; (vii) shortages of or delays in receiving raw materials;
or (viii) shortage of adequate power or transportation facilities (each, a “Force Majeure Event”).

 

[REMAINDER
OF PAGE LEFT BLANK]

 

    	 	 	 

    	 

    

 

IN
WITNESS WHEREOF, the Parties hereto has executed this Note on June 6, 2019.

 

	 	NUTRALIFE
        BIOSCIENCES, INC.

        
	 	 	PHYTOCHEM
        TECHNOLOGIES, INC.

        

	 	 	 	 	 
	By:	 	 	By:	 
	 	Edgar
    Ward, Chief Executive Officer	 	 	Edgar
    Ward, Chief Executive Officer
	 	 	 	 	 
	 	Address
    for Notice:	 	 	Address
    for Notice:
	 	NutraLife
    Biosciences, Inc.	 	 	NutraLife
    Biosciences, Inc.
	 	Attn:
    Edgar Ward, Chief Executive Officer	 	 	Attn:
    Edgar Ward, Chief Executive Officer
	 	6601
    Lyons Rd. L-6	 	 	6601
    Lyons Rd. L-6
	 	Coconut
    Creek, Fl. 33073	 	 	Coconut
    Creek, Fl. 33073
	 	edgar@NutraFuels.com	 	 	edgar@NutraFuels.comExhibit
10.31

 

EXHIBIT
C: SECURITY AGREEMENT

 

This
Security Agreement (this “Security Agreement”), is made and effective as of the day set forth on the signature
page hereto by and between NutraLife Biosciences, Inc. (“NutraLife”), PhytoChem Technologies, Inc. (“PhytoChem”),
a Florida corporation (NutraLife and PhytoChem are collectively referred to herein as the “Company”), and Kahn Family
Limited PT II (the “Purchaser”) effective as of the date on the signature page hereto. The Company and the Purchaser
are referred to herein collectively as the “Parties”, or individually as a “Party”.

 

ARTICLE
1. RECITALS

 

The
Recitals below are incorporated herein and made terms of this Security Agreement.

 

WHEREAS,
the Company obtained certain rights to commercialize and monetize certain technology and phytoextractor equipment known as
the Ennea Processor (“Ennea” or “Ennea Processor”) pursuant to an agreement by and between Owen J. Morgan
(“Morgan”) and the Company dated February 4, 2019 (the “Morgan Agreement”).

 

WHEREAS,
the Ennea uses certain technologies to separate, process and/or extract bioactive compounds including cannabinoids
from hemp and other plants to remove and/or modify, purify, dilute and extract bioactive ingredients and/or remove unwanted
substances to produce finished products for a variety of applications;

 

WHEREAS,
the Company requires capital to manufacture, purchase, monetize and commercialize the Ennea;

 

WHEREAS,
the Company desires to issue and sell, and the Purchaser desires to purchase a full recourse secured convertible promissory
note (the “Note”) as attached as Exhibit B to the Investment Agreement in the principal amount of $1,000,000
(“Principal” or the “Principal Amount”);

 

WHEREAS,
the Collateral Ennea Processor machines (“Collateral Processors”) shall serve as collateral for the Principal
Amount pursuant to the terms of the Security Agreement (the “Security Agreement”) so long as any portion of the Principal
Amount is outstanding; and

 

NOW,
THEREFORE, under the terms hereof, the Purchaser desires to obtain and the Company desires to grant the Purchaser security
for the Note under the terms hereof.

 

ARTICLE
1. DEFINITIONS.

 

ARTICLE
1.1 “Collateral Processors” shall mean the first four (4) of the Ennea Processors monetized and/or commercialized
by the Company pursuant to the Morgan Agreement.

 

ARTICLE
1.2 “UCC” means the Uniform Commercial Code, as adopted and enacted and as in effect from time to time
in the State of Florida. Terms used herein which are defined in the UCC and not otherwise defined herein shall have the respective
meanings ascribed to such terms in the UCC.

 

    	 

    	 

    

 

ARTICLE
2. GRANT OF SECURITY INTEREST.

 

ARTICLE
2.1 GRANT. To secure the Obligations, the Company, as Company, hereby assigns and grants to the Purchaser, as Purchaser, a
continuing lien on and security interest in the Collateral.

 

ARTICLE
3. REPRESENTATIONS AND WARRANTIES.

 

ARTICLE
3.1 The Company represents, warrants and covenants to the Purchaser that: (a) the Company has good, marketable and indefeasible
title to the Collateral, has not made any prior sale, pledge, encumbrance, assignment or other disposition of any of the Collateral,
and the Collateral is free from all encumbrances and rights of setoff of any kind except the lien in favor of the Purchaser created
by this Security Agreement; (b) except as herein provided, the Company will not hereafter without the Purchaser’s prior
written consent sell, pledge, encumber, assign or otherwise dispose of any of the Collateral or permit any right of setoff, lien
or security interest to exist thereon except to the Purchaser; and (c) the Company will defend the Collateral against all claims
and demands of all persons at any time claiming the same or any interest therein.

 

ARTICLE
4. COMPANY’S COVENANTS.

 

ARTICLE
4.1 The Company covenants that it shall:

 

(a)
from time to time and at all reasonable times allow the Purchaser, by or through any of its officers, agents, attorneys, or accountants,
to examine or inspect the Collateral, and obtain valuations and audits of the Collateral, at the Company’s expense, wherever
located. The Company shall do, obtain, make, execute and deliver all such additional and further acts, things, deeds, assurances
and instruments as the Purchaser may require to vest in and assure to the Purchaser its rights hereunder and in or to the Collateral,
and the proceeds thereof.

 

(b)
keep the Collateral in good order and repair at all times and immediately notify the Purchaser of any event causing a material
loss or decline in value of the Collateral, whether or not covered by insurance, and the amount of such loss or depreciation;

 

(c)
only use or permit the Collateral to be used in accordance with all applicable federal, state, county and municipal laws and regulations;
and

 

(d)
have and maintain insurance at all times with respect to all Collateral against risks of fire (including so-called extended coverage),
theft, sprinkler leakage, and other risks (including risk of flood if any Collateral is maintained at a location in a flood hazard
zone) as the Purchaser may reasonably require, in such form, in the minimum amount of the outstanding principal of the Note and
written by such companies as may be reasonably satisfactory to the Purchaser. Each such casualty insurance policy shall contain
a standard Lender’s Loss Payable Clause issued in favor of the Purchaser under which all losses thereunder shall be paid
to the Purchaser as the Purchaser’s interest may appear. Such policies shall expressly provide that the requisite insurance
cannot be altered or canceled without at least thirty (30) days prior written notice to the Purchaser and shall insure the Purchaser
notwithstanding the act or neglect of the Company. Upon the Purchaser’s demand, the Company shall furnish the Purchaser
with evidence of insurance as the Purchaser may require. In the event of failure to provide insurance as herein provided, the
Purchaser may, at its option, obtain such insurance and the Company shall pay to the Purchaser, on demand, the cost thereof. Proceeds
of insurance shall be applied by the Purchaser to reduce the Mortgage as defined in the Transaction Documents.

 

    	 

    	 

    

 

(e)
If the Collateral is, at any time, in the possession of a bailee, Company shall promptly notify Purchaser thereof and, if requested
by Purchaser, shall promptly obtain an acknowledgment from the bailee, in form and substance satisfactory to Purchaser, that the
bailee holds such Collateral for the benefit of Purchaser and shall act upon the instructions of Purchaser, without the further
consent of Company.

 

ARTICLE
5. NO TRANSFER.

 

ARTICLE
5.1 NEGATIVE PLEDGE. The Company will not sell or offer to sell or otherwise transfer or grant or allow the imposition of
a lien or security interest upon the Collateral or use any portion thereof in any manner inconsistent with this Security Agreement
or with the terms and conditions of any policy of insurance thereon.

 

ARTICLE
6. FURTHER ASSURANCES.

 

ARTICLE
6.1 UCC FILINGS. The Company hereby irrevocably authorizes Purchaser at any time and from time to time to file in any Uniform
Commercial Code jurisdiction any initial financing statements and amendments thereto that (a) indicate the Collateral (i) as all
assets of Company or words of similar effect, regardless of whether any particular asset comprised in the Collateral falls within
the scope of Article 9 of the Florida Uniform Commercial Code or such jurisdiction, or (ii) as being of an equal or lesser scope
or with greater detail, and (b) contain any other information required by part 5 of Article 9 of the Florida Uniform Commercial
Code for the sufficiency or filing office acceptance of any financing statement or amendment, including, but not limited to (i)
whether the Company is an organization, the type of organization and (ii) any organization identification number issued to Company.
Company agrees to furnish any such information to purchaser promptly upon request. company also ratifies its authorization for
purchaser to have filed in any uniform commercial code jurisdiction any like initial financing statements or amendments thereto
if filed prior to the date hereof.

 

ARTICLE
7. EVENTS OF DEFAULT.

 

ARTICLE
7. 1 TERMS OF DEFAULT. The Company shall, at the Purchaser’s option, be in default under this Security Agreement upon
the happening of any of the following events or conditions (each, an “Event of Default”): (a) a failure to pay any
amount due under the Note or this Security Agreement within fifteen (15) days of the date the same is due; (b) the failure by
the Company to perform any of its other obligations under this Security Agreement within thirty (30) days of notice from Purchaser
of the same; (c) falsity, inaccuracy or material breach by the Company of any written warranty, representation or statement made
or furnished to the Purchaser by or on behalf of the Company; (d) an uninsured material loss, theft, damage, or destruction to
any of the Collateral, or the entry of any judgment against the Company or any lien against or the making of any levy, seizure
or attachment of or on the Collateral; or (e) the failure of the Purchaser to have a perfected first priority security interest
in the Collateral.

 

ARTICLE
8. REMEDIES.

 

ARTICLE
8.1 REMEDIES UPON DEFAULT. Upon the occurrence of any such Event of Default and at any time thereafter, the Purchaser may
declare all Obligations secured hereby immediately due and payable and shall have, in addition to any remedies provided herein
or by any applicable law or in equity, all the remedies of a secured party under the UCC. The Purchaser’s remedies include,
but are not limited to, to the extent permitted by law, the right to (a) peaceably by its own means or with judicial assistance
enter the Company’s premises and take possession of the Collateral without prior notice to the Company or the opportunity
for a hearing, (b) render the Collateral unusable, (c) dispose of the Collateral on the Company’s premises, and (d) require
the Company to assemble the Collateral and make it available to the Purchaser at a place designated by the Purchaser. Unless the
Collateral is perishable or threatens to decline speedily in value or is of a type customarily sold on a recognized market, the
Purchaser will give the Company reasonable notice of the time and place of any public sale thereof or of the time after which
any private sale or any other intended disposition thereof is to be made. The requirements of commercially reasonable notice shall
be met if such notice is sent to the Company at least fifteen (15) days before the time of the intended sale or disposition. Expenses
of retaking, holding, preparing for sale, selling or the like shall include the Purchaser’s reasonable attorney’s
fees and legal expenses, incurred or expended by the Purchaser to enforce any payment due it under this Security Agreement either
as against the Company, or in the prosecution or defense of any action, or concerning any matter growing out of or connection
with the subject matter of this Security Agreement and the Collateral pledged hereunder. The Company waives all relief from all
appraisement or exemption laws now in force or hereafter enacted.

 

    	 

    	 

    

 

ARTICLE
9. PAYMENT OF EXPENSES.

 

ARTICLE
9.1 EXPENSES. At its option, the Purchaser may, but is not required to: discharge taxes, liens, security interests or such
other encumbrances as may attach to the Collateral; pay for required insurance on the Collateral; and pay for the maintenance,
appraisal or reappraisal, and preservation of the Collateral, as determined by the Purchaser to be necessary. The Company will
reimburse the Purchaser on demand for any payment so made or any expense incurred by the Purchaser pursuant to the foregoing authorization,
and the Collateral also will secure any advances or payments so made or expenses so incurred by the Purchaser.

ARTICLE 10. MISCELLANEOUS

 

ARTICLE
10.1 NOTICES. All notices, demands, requests, consents, approvals and other communications required or permitted hereunder
must be in writing and will be effective upon receipt. Such notices and other communications may be hand-delivered, sent by facsimile
transmission with confirmation of delivery and a copy sent by first-class mail, or sent by nationally recognized overnight courier
service, to a party’s address set forth above or to such other address as any party may give to the other in writing for
such purpose.

 

ARTICLE
10.2 PRESERVATION OF RIGHTS. No delay or omission on the Purchaser’s part to exercise any right or power arising hereunder
will impair any such right or power or be considered a waiver of any such right or power, nor will the Purchaser’s action
or inaction impair any such right or power. The Purchaser’s rights and remedies hereunder are cumulative and not exclusive
of any other rights or remedies which the Purchaser may have under other agreements, at law or in equity.

 

ARTICLE
10.3 ILLEGALITY. In case any one or more of the provisions contained in this Security Agreement should be invalid, illegal
or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein shall
not in any way be affected or impaired thereby.

 

ARTICLE
10.4 CHANGES IN WRITING. No modification, amendment or waiver of any provision of this Security Agreement nor consent to
any departure by the Company therefrom will be effective unless made in a writing signed by the Purchaser, and then such waiver
or consent shall be effective only in the specific instance and for the purpose for which given. No notice to or demand on the
Company in any case will entitle the Company to any other or further notice or demand in the same, similar or other circumstance.

 

    	 

    	 

    

 

ARTICLE
10.5 ENTIRE AGREEMENT. This Security Agreement (including the documents and instruments referred to herein) constitutes the
entire agreement and supersedes all other prior agreements and understandings, both written and oral, between the parties with
respect to the subject matter hereof.

 

ARTICLE
10.6 COUNTERPARTS. This Security Agreement may be signed in any number of counterpart copies and by the parties hereto on
separate counterparts, but all such copies shall constitute one and the same instrument. Delivery of an executed counterpart of
a signature page to this Security Agreement by facsimile transmission shall be effective as delivery of a manually executed counterpart.
Any party so executing this Security Agreement by facsimile transmission shall promptly deliver a manually executed counterpart,
provided that any failure to do so shall not affect the validity of the counterpart executed by facsimile transmission.

 

ARTICLE
10.7 SUCCESSORS AND ASSIGNS. This Security Agreement will be binding upon and inure to the benefit of the Company and the
Purchaser and their respective heirs, executors, administrators, successors and assigns; provided, however, that the Company may
not assign this Security Agreement in whole or in part without the Purchaser’s prior written consent and the Purchaser at
any time may assign this Security Agreement in whole or in part.

 

ARTICLE
10.8 INTERPRETATION. In this Security Agreement, unless the Purchaser and the Company otherwise agree in writing, the singular
includes the plural and the plural the singular; words importing any gender include the other genders; references to statutes
are to be construed as including all statutory provisions consolidating, amending or replacing the statute referred to; the word
“or” shall be deemed to include “and/or”, the words “including”, “includes” and
“include” shall be deemed to be followed by the words “without limitation”; references to articles, sections
(or subdivisions of sections) or exhibits are to those of this Security Agreement unless otherwise indicated. Article headings
in this Security Agreement are included for convenience of reference only and shall not constitute a part of this Security Agreement
for any other purpose.

 

ARTICLE
10.9 WAIVER OF CONFLICTS. The Company and the Purchaser each acknowledge that the Pledgor, Brenda Hamilton and her law firm,
Hamilton & Associates Law Group, P.A has in the past performed, and may continue to perform, legal and/or consulting services
for the Company in connection with the Transaction Documents and the matters and transactions described in this Security Agreement
as well as in matters unrelated to the Transaction Documents. Accordingly, the Company and Purchaser each hereby acknowledges
that they have been advised by Brenda Hamilton & Hamilton & Associates Law Group, P.A. to seek the advice of independent
legal counsel in connection with the Transaction Documents including with respect to the Pledge Agreement, Mortgage and Pledgor
Royal Agreement in which Brenda Hamilton is a Party and the transactions contemplated thereby. Additionally, the Company and Purchaser
each acknowledge that they have had an opportunity to ask for information relevant to this disclosure and has consulted with independent
legal counsel or has had the opportunity to do so and gives its informed consent to Brenda Hamilton & Hamilton & Associates
Law Group, P.A. representation of and/or performance of services for the Company in the connection with the Transaction Documents
and transactions contemplated thereby.

 

    	 

    	 

    

 

10.10
GOVERNING LAW AND JURISDICTION. This Security Agreement shall be governed by and construed in accordance with the laws of
the State of Florida without regard to principles of conflict law applicable to contracts made and to be performed with such state.
Each of the parties hereto accepts for itself to the jurisdiction of Palm Beach County Florida and irrevocably consents to such
jurisdiction in any proceedings and waives any objection to venue laid therein. Any controversy or claim arising out of or relating
of this Security Agreement shall be settled by binding arbitration administered by the American Arbitration Association and judgment
on the award entered in any court having jurisdiction. The arbitration proceedings shall be conducted before a panel of three
neutral arbitrators in Palm Beach County, Florida all of whom shall be members of the bar of the state of Florida, actively engaged
in the practice of law for at least ten (10) years. Either Party hereto may apply to the arbitrator seeking injunctive relief
until the arbitration award is rendered or the controversy otherwise resolved. Either Party may, without waiving any remedy under
this Security Agreement, seek from any court having jurisdiction any interim or provisional relief that is necessary to protect
the rights or property of that party, pending the arbitral tribunal’s determination of the merits of the controversy. Each
party shall bear its own costs, expenses and attorney fees and an equal share of the arbitrators’ and administrative fees
of arbitration. Except as may be required by law, neither a party nor an arbitrator may disclose the existence content or results
of any arbitration hereunder without the prior written consent of the Parties. All documents, testimony and records shall be received,
heard and maintained by the arbitrators in secrecy, available for the inspection only of the Parties to this Security Agreement
and their respective attorneys and their respective experts who shall agree in advance and in writing to receive all such information
confidentially and to maintain such information in secrecy until such information shall become generally known. In consideration
for and as a material condition of this Security Agreement, each Party agrees that final and binding arbitration is the exclusive
means for resolving any claim or controversy arising out of or related to this Security Agreement. This Agreement is a waiver
of all rights the Parties may have to a civil court action. Accordingly, only an arbitrator, not a judge or jury, will decide
the dispute, although the arbitrator has the authority to award any type of relief that could otherwise be awarded by a judge
or jury.

 

IN
WITNESS WHEREOF, the Parties hereto have executed this Security Agreement on June 6, 2019.

 

	NUTRALIFE
    BIOSCIENCES, INC.	 	KAHN
    FAMILY LIMITED PT II
	 	 	 	 	 
	By:	                                  	 	By:	                      
	 	Edgar
    Ward, Chief Executive Officer	 	 	(Signature)
	 	 	 	 	 
	 	 	 	 	 
	PHYTOCHEM
    TECHNOLOGIES, INC.	 	 	(Print
    Name)
	 	 	 	 
	By:	 	 	 	 
	 	Edgar
    Ward, Chief Executive Officer	 	 	(Print
    Title)
	 	 	 	 
	Address
    for Notice:	 	Address for Notice:
	 	 	 	 
	NutraLife
    Biosciences, Inc.	 	 	 
	Attn:
    Edgar Ward, Chief Executive Officer	 		 
	6601
    Lyons Rd. L-6	 	Phone: 	 
	Coconut
    Creek, Fl. 33073	 	Email: 	 
	edgar@NutraFuels.com

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00324-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00324-of-00352.parquet"}]]